JP2019516785A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516785A5
JP2019516785A5 JP2019508294A JP2019508294A JP2019516785A5 JP 2019516785 A5 JP2019516785 A5 JP 2019516785A5 JP 2019508294 A JP2019508294 A JP 2019508294A JP 2019508294 A JP2019508294 A JP 2019508294A JP 2019516785 A5 JP2019516785 A5 JP 2019516785A5
Authority
JP
Japan
Prior art keywords
disease
cancer
binding domain
seq
domain according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019508294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516785A (ja
JP7133544B2 (ja
Filing date
Publication date
Priority claimed from GBGB1607636.6A external-priority patent/GB201607636D0/en
Priority claimed from GBGB1607828.9A external-priority patent/GB201607828D0/en
Application filed filed Critical
Priority claimed from PCT/EP2017/060266 external-priority patent/WO2017191062A1/en
Publication of JP2019516785A publication Critical patent/JP2019516785A/ja
Publication of JP2019516785A5 publication Critical patent/JP2019516785A5/ja
Priority to JP2022075986A priority Critical patent/JP2022115961A/ja
Application granted granted Critical
Publication of JP7133544B2 publication Critical patent/JP7133544B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019508294A 2016-05-01 2017-04-28 親和性を操作した血清タンパク質担体結合ドメイン Active JP7133544B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022075986A JP2022115961A (ja) 2016-05-01 2022-05-02 親和性を操作した血清タンパク質担体結合ドメイン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1607636.6 2016-05-01
GBGB1607636.6A GB201607636D0 (en) 2016-05-01 2016-05-01 Molecules & method
GB1607828.9 2016-05-04
GBGB1607828.9A GB201607828D0 (en) 2016-05-04 2016-05-04 Method
PCT/EP2017/060266 WO2017191062A1 (en) 2016-05-01 2017-04-28 Affinity engineered serum protein carrier binding domain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022075986A Division JP2022115961A (ja) 2016-05-01 2022-05-02 親和性を操作した血清タンパク質担体結合ドメイン

Publications (3)

Publication Number Publication Date
JP2019516785A JP2019516785A (ja) 2019-06-20
JP2019516785A5 true JP2019516785A5 (enExample) 2020-05-28
JP7133544B2 JP7133544B2 (ja) 2022-09-08

Family

ID=58707502

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508294A Active JP7133544B2 (ja) 2016-05-01 2017-04-28 親和性を操作した血清タンパク質担体結合ドメイン
JP2022075986A Abandoned JP2022115961A (ja) 2016-05-01 2022-05-02 親和性を操作した血清タンパク質担体結合ドメイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022075986A Abandoned JP2022115961A (ja) 2016-05-01 2022-05-02 親和性を操作した血清タンパク質担体結合ドメイン

Country Status (8)

Country Link
US (1) US11466076B2 (enExample)
EP (1) EP3452506B1 (enExample)
JP (2) JP7133544B2 (enExample)
CN (1) CN109071643B (enExample)
BR (1) BR112018071288A2 (enExample)
CA (1) CA3022494A1 (enExample)
ES (1) ES3035839T3 (enExample)
WO (1) WO2017191062A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201811368D0 (en) * 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
CA3198049A1 (en) 2020-10-15 2022-04-21 UCB Biopharma SRL Binding molecules that multimerise cd45
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
DK1644412T4 (en) 2003-07-01 2018-11-12 Ucb Biopharma Sprl MODIFIED ANTIBODY-FAB FRAGMENTS
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
ES2622460T3 (es) * 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
SI2334705T1 (sl) 2008-09-26 2017-05-31 Ucb Biopharma Sprl Biološki produkti
MX351502B (es) * 2011-11-11 2017-10-18 Ucb Pharma Sa Anticuerpos de union de albumina y fragmentos de union de los mismos.
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
US10407508B2 (en) * 2013-07-08 2019-09-10 Nanjing Legend Biotech., Ltd. Compositions and methods for increasing protein half-life in a serum
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct

Similar Documents

Publication Publication Date Title
JP2019516785A5 (enExample)
JP2020513804A5 (enExample)
HRP20161069T1 (hr) Molekule antitijela koje vezuju il-17a i il-17f
HRP20141214T1 (hr) Molekule antitijela sa specifiäśnosti za humani 6-il
JP2015525768A5 (enExample)
JP2019503167A5 (enExample)
JP2020501532A5 (enExample)
JP2019514876A5 (enExample)
JP2011083291A5 (enExample)
JP2019506841A5 (enExample)
JP2019514882A5 (enExample)
JP2019531093A5 (enExample)
JP2019523753A5 (enExample)
JP2018538281A5 (enExample)
JP2018198596A5 (enExample)
JP2014515602A5 (enExample)
JP2016517273A5 (enExample)
JP2010273685A5 (enExample)
JP2017507181A5 (enExample)
JP2017536412A5 (enExample)
JP2015523323A5 (enExample)
HRP20231264T1 (hr) Protutijela protiv csf-1r
JP2015096070A5 (enExample)
JP2018524001A5 (enExample)
WO2017009308A3 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof